April 18th 2024
The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
MPDL3280A Induces Durable Responses in NSCLC, Other Cancers
November 21st 2013MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.
Read More
Afatinib for <em>EGFR</em> Mutation-Positive, Advanced Non-Small Cell Lung Cancer
November 11th 2013Activating EGFR mutations are associated with response to TKIs. Afatinib (Gilotrif) is an oral, irreversible ErbB family TKI that targets EGFR, HER2, and ErbB4. Afatinib is being formally evaluated in the LUX-Lung clinical trial program for NSCLC.
Read More
The Risk of Pneumonitis From Radiation in Patients With Lung Cancer
October 9th 2013Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Watch
Anti-PD-1 Antibody MK-3475 Shows Promise in NSCLC
October 3rd 2013MK-3475, an investigational immunotherapy, has demonstrated an objective response rate (ORR) of up to 24% in patients with previously treated non-small cell lung cancer (NSCLC), according to interim results from a phase Ib expansion study.
Read More
Advances in Non-Small Cell Lung Cancer
September 30th 2013Individualized treatment protocols for patients are becoming increasingly important in the management of NSCLC. Consequently, drug research continues to focus on regimens that select therapy according to the molecular characteristics of the tumor.
Read More